What does Alpheus Medical do?
Alpheus Medical is a clinical-stage oncology company focused on developing a non-thermal, tumor-selective therapy. Their platform uses low-intensity diffuse ultrasound (LIDU) in combination with oral 5-aminolevulinic acid (5-ALA) to selectively target and destroy cancer cells across the brain, all without the need for imaging or sedation.
How much did they raise?
The company raised $52M in a Series B funding round led by HealthQuest Capital and Samsara BioCapital, with participation from OrbiMed, Action Potential Venture Capita, BrightEdge, the Brain Tumor Investment Fund, and Sontag Innovation Fund.
What are their plans for the money?
The funds will be used to support a Phase 2B randomized controlled trial (RCT) evaluating the efficacy of Selective Destruction Therapy (SDT) in patients with newly diagnosed glioblastoma. If successful, this could introduce a transformative outpatient treatment option in oncology.
What have they achieved so far?
Alpheus Medical has already developed a pioneering platform that delivers non-thermal, tumor-selective therapy. This innovation sets the stage for its Phase 2B trial, marking an important milestone in the clinical validation of their approach.
